Skip to main content

RT @drdavidliew: Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT sur

Nov 14, 2022 3:52 pm
Social Author Name
David Liew
Tweet Content
Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsivenessđź‘€) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×